Renal Cell Carcinoma | Disease Landscape & Forecast | G7 | 2024
The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer) or Lenvima / Kisplyx (Eisai), and Opdivo plus Cabometyx (Exelixis / Ipsen), have revolutionized the first-line treatment of advanced and metastatic disease, and the expected approvals of triplet regimens combining immune checkpoint inhibitors with tyrosine kinase inhibitors will further diversify the first-line setting. During the forecast period, the anticipated entry of savolitinib (AstraZeneca) and zanzalintinib (Exelixis) will provide effective first-line options specifically for patients with non-clear-cell histologies. The adjuvant setting will experience the most growth owing to the increased uptake of Keytruda as a monotherapy and in combination with Welireg—Merck & Co.’s HIF-2α inhibitor—for the treatment of early-stage RCC.
Questions answered
- How are immune checkpoint inhibitors shaping the adjuvant treatment of early-stage RCC and the first-line treatment of advanced or metastatic disease?
- How will further approvals for Merck & Co.’s Welireg change treatment sequencing in the later-line settings?
- What are the key unmet needs in the treatment of RCC?
- Which are the most promising regimens in the late-phase pipeline, and how will they shape the future of the RCC therapy market over the forecast period?
Geography: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading medical oncologists / urologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and recurrent incident cases of renal cell carcinoma by country, segmented by drug-treatable and drug-treated early-stage and advanced or metastatic disease, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key renal cell carcinoma therapies through 2033, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
